Werfen today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Aptiva® ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell rating on IGMS stock.

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is enacting lay-offs, cutting 73% of jobs.

Ouro Medicines, a new biotechnology startup, launched Friday with $120 million in funding to develop antibody drugs for ...

The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

IGM Biosciences (NASDAQ:IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates, imvotamab and IGM-2644, in the wake of disappointing data. The ...

Nicki Chapman was left lost for words during a recent episode of Escape to the Country as she visited a couple six years after buying their dream home.

Buy IGM near 102.34 target 107.14 stop loss @ 102.04 Details The technical summary data tells us to buy IGM near 102.34 with an upside target of 107.14. This data also tells us to set a stop loss @ ...